Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN 8 5 PH6 versus NEPHRAMINE 5 4.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN 8 5 PH6 versus NEPHRAMINE 5 4.
AMINOSYN 8.5% (PH6) vs NEPHRAMINE 5.4%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminosyn 8.5% (pH 6) provides a mixture of essential and nonessential amino acids for protein synthesis and nitrogen balance maintenance in patients unable to tolerate oral or enteral nutrition.
Provides essential amino acids for protein synthesis in patients with renal impairment, reducing nitrogen waste accumulation.
1-1.5 g amino acids/kg/day intravenously, typically 500 mL of a 8.5% solution (42.5 g amino acids) infused over 8-24 hours.
500 mL to 1000 mL intravenously over 8-24 hours, containing 5.4% amino acids, typically as a component of total parenteral nutrition; dose adjusted based on metabolic needs and protein requirements (usual 0.8-1.5 g/kg/day amino acids).
None Documented
None Documented
Not applicable as a fixed value; elimination half-life of individual amino acids varies (minutes to hours) and is dependent on metabolic demand and renal function.
1-2 hours (endogenous amino acid pool turnover); clinical context: continuous infusion required to maintain plasma levels.
Primarily renal; elimination depends on metabolic utilization. Unused amino acids are deaminated and excreted as urea in urine (over 90%). Fecal elimination is negligible.
Renal: >90% as amino acids and metabolites. Biliary/fecal: negligible.
Category C
Category C
Amino Acid Solution
Amino Acid Solution